|
France Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The France Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for France .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the French pharmaceutical and healthcare industry.
Competitive intelligence, French pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the French market.
The France Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s France Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the French pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on France to test other views – a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the French Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France .
- Exploit The Latest Competitive French Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in France .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
France Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| France Political SWOT |
| France Economic SWOT |
| France Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceutical Business Environment Rankings |
| Risks to Realisation of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Counterfeit Drugs |
| Pricing and Reimbursement Issues |
| France Reimbursement Categories |
| Healthcare Sector |
| Public Health Issues |
| Epidemiology |
| Table: Disease Burden In Western Europe |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: France Drug Market Expenditure Forecast Indicators, 2004-2013 |
| Key Factors – Industry |
| Table: France's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: France - Economic Activity, 2006 – 2013 |
| Prescription Market Forecast |
| Table: France – Prescription Drugs Market Forecast, 2004-2013 |
| OTC Market Forecast |
| Table: France OTC Drugs Market Forecast Indicators, 2004-2013 (US$bn unless otherwise stated) |
| Patented Market Forecast |
| Table: France Patented Drugs Market Forecast Indicators, 2004-2013 |
| Generics Market Forecasts |
| Table: France's Generics Market Indicators, 2004-2013 |
| Export/Import Forecasts |
| Table: Sectoral Trade Indicators 2004-2013, (US$mn) |
| Other Healthcare Data and Forecasts |
| Table: Socio-Demographic Indicators, 2004-2013 |
| Key Risks to BMI's Forecasts |
Chapter - Competitive Landscape |
| Multinational Companies |
| Generics Sector |
| Clinical Research |
| Research and Development Sector |
| Biotechnology Sector |
| Table: New French Taxes On Private-Sector Research Applications |
| Wholesale Sector |
| Pharmacy Sector |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| Sanofi-Aventis |
| Pfizer |
| GlaxoSmithKline (GSK) |
| Novartis |
| Merck & Co |
| Major Indigenous Companies |
| Servier |
| Ipsen |
Chapter - Country Snapshot: France Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2000-2005 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
France Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI calculates France’s pharmaceutical expenditure to have been EUR34.07bn (US$48.67bn) in 2008. By 2013, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have reached a value of EUR39.30bn (US$49.75bn) equating to a compound annual growth rate (CAGR) of 2.9% in local currency terms.
Mid-sized to small specialty pharmaceutical companies in France are experiencing a drastic shortage in funding. France is home to over 300 biotech firms, but the international financial crisis means there is a low appetite for risk and less likelihood of investment for development stage companies, which include most biotechnology firms. France Biotech’s Drug Pipeline Review, published in March 2009, revealed that funding for the country’s life sciences industry fell to EUR143mn (US$180mn) in 2008 compared to EUR694mn (US$880mn) in 2007, equating to a staggering 79% reduction in investments.
BMI believes it is unlikely the French biotech industry will obtain an increase in government funding as the French government has reportedly weakened its support for young, innovative companies during 2009. The budget for the OSEO state innovation agency has been cut by half, to US$415mn. Additionally, reform of the research tax credit led to an average annual reduction of 56% for biotech companies incorporated within the last five years.
France has one of the world’s highest levels of per capita drug expenditure, estimated to have reached US$764 in 2008. In 2008, pharmaceutical spending as a percent of GDP dropped to 1.70%, compared to 1.76% in 2007. This figure is forecast to increase to 1.83% of GDP in 2009; however, figures are expected to decrease to 2007 levels by 2013. The French government is focused on reducing pharmaceutical expenditure in order to cut the country’s healthcare budget deficit. The role of the Haute Autorité de santé (HAS) – or French National Authority for Health – was extended in January 2009 and one its major responsibilities will be to devise rational, cost-effective reimbursement policies for drugs, rather than purely focusing on therapeutic benefits.
In January 2009, the French Pharmaceutical Companies Assciation (LEEM)’s biennial survey of international phase II and III clinical trials revealed that France’s appeal as a location for clinical trials appears to be fading slightly, relative to other European and Asian countries. Despite improvements in the number of patients recruited per trial and the speed at which they were recruited, the emergence of cheaper destinations in which to base trials, along with improvements in conditions among fellow Western European countries, has resulted in a slight reduction in patient recruitment share.
|
France Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |